Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsSolid TumorsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyIndolent LymphomasNeuro-OncologyT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMalignant MeningitisMantle Cell LymphomaNHL, B-Cell Type, Anaplastic Large Cell Lymphoma, ALK-PositiveNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoblastic LymphomaNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Lymphoblastic LymphomaSubgroupB-ALLCD22+Leukemic MeningitisPh/BCR-ABL+Ph/BCR-ABL-T-ALLunfitICD10C79.3C82.-C82.7C82.9C83.1C83.3C83.5C83.7C84.6C91.0-C91.1-C91.5-MeSHBurkitt LymphomaLymphoma, FollicularLymphoma, Mantle-CellMeningeal CarcinomatosisPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaSequenceALL, Mini-hyperCVD/Inotuzumab Ozogamicin: Mini-hyperCVD (CYCL150/VNCR2/DEXA20)/INTZ(0.6/0.3)/RITU375, ALL/NHL, C1 (PID2098) -|- C2 (PID2097) -|- C3 (PID2099) -|- C4 (PID2097) -|- maint. (PID313)ALL,Ph/BCR-ABL+: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375/IMAT800, ALL/NHL, Ph/BCR-ABL+, C1 (PID2084) -|- C2 (PID2085) -|- C3 (PID2086) -|-C4 (PID2085) -|- C5 (PID2087) -|- C6 (PID2088) -|- C7 (PID2089) -|- C8 (PID2090) -|- Month 1-5 (PID2073) -|- Month 6 (PID2110) -|- Month 7 (PID2113) -|- Month 8-17 (PID2073) -|- Month 18 (PID2110) -|- Month 19 (PID2113) -|- Month 20-24 (PID2073)B-ALL/recurrent therapy: mini-hyperCVD (CYCL150/VNCR2/DEXA20)/INTZ(0.6/0.3)/RITU375, ALL/NHL, C1 (PID2098) -|- C2 (PID2097) -|- C3 (PID2099) -|- C4 (PID2097) -|- C1 (PID2117) -|- C2-4 (PID2118) -|- maint., Month 1-12 (PID2119) -|- maint., month 13-36 (PID2120)B-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, B-ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C5 (PID2063) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2074) -|- Month 7 (PID2061) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)GMALL-ALL - FrailGMALL-ALL - Frail Ph/BCR-ABL+GMALL 08/2013-ALL/LBL, 56 - 75GMALL 08/2013-ALL/LBL, 56 - 75, Ph/BCR-ABL+GMALL 08/2013-ALL/LBL 18 - 55GMALL 08/2013-ALL/LBL 18 - 55, Ph/BCR-ABL+GMALL 08/2013-B-ALL/NHL 2002 Regimen, 18 - 55GMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, B-ALL onlyGMALL 08/2013-B-ALL/NHL 2002 regimen, older than 55, NHL onlyIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)R-ICE (RITU375/ETOP100/CRBP635/IFOS3), Burkitt's Lymphoma, C1-2 (PID2223) -|- C3 (PID2224).T-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C4N (PID2083) -|- C5 (PID2063) -|- C5N (PID2083) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2083) -|- Month 7 (PID2083) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)ChemotherapyChemo-substanceAsparaginaseBlinatumomabCarboplatinCladribineClofarabinCyclophosphamideCytarabineDasatinibDaunorubicinDexamethasoneDoxorubicinEtoposideFludarabineIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateMethylprednisoloneNelarabineNilotinibPeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceAsparaginaseBlinatumomabCarboplatinCladribineClofarabinCyclophosphamideCytarabineDasatinibDaunorubicinDexamethasoneDoxorubicinEtoposideFludarabineIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateMethylprednisoloneNelarabineNilotinibPeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceAsparaginaseBlinatumomabCarboplatinCladribineClofarabinCyclophosphamideCytarabineDasatinibDaunorubicinDexamethasoneDoxorubicinEtoposideFludarabineIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateMethylprednisoloneNelarabineNilotinibPeg asparaginasePrednisoloneRituximabVincristineVindesineChemo-substanceAsparaginaseBlinatumomabCarboplatinCladribineClofarabinCyclophosphamideCytarabineDasatinibDaunorubicinDexamethasoneDoxorubicinEtoposideFludarabineIdarubicinIfosfamideImatinibInotuzumab OzogamicinMercaptopurineMethotrexateMethylprednisoloneNelarabineNilotinibPeg asparaginasePrednisoloneRituximabVincristineVindesineNo. Substances12345678 RadiotherapySupportive therapySupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidValaciclovirSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidValaciclovirSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidValaciclovirSupportive substanceAciclovirAmphotericin BBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneDextrose 5%DimetindenFamotidineFilgrastimFolinic acidFosaprepitantFurosemideGranisetronMesnaNaCl 0.9%ParacetamolPegfilgrastimPotassium chloridePrednisoloneSodium BicarbonateUrsodeoxycholic acidValaciclovirNo. Substances12345678910111213141516Protocol classificationTherapy classificationalternativecurrent standardStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseautologous stem cell transplantationConsolidationInductionMaintenancePre-phaseReinductionSalvageseveral possibleTherapy intentioncurativecurative or palliativedisease controlpalliativeRisksAnemia Hb below 8g/dlAstheniaBleedingCardiotoxicityCMV Infection (asympt. + sympt.)ConstipationCytokine Release SyndromeDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHepatotoxicityHyperbilirubinemiaHyperglycemiaHypertensionHypokalemiaIncrease AminotransferasesInfectionsInfusion ReactionMucositisMyalgiasNeuropathyNeurotoxicityNeutropeniaOral MucositisPleural EffusionPneumoniaPyrexiaRashRenal FailureSeizuresSepsisThrombocytopenia below 50 000/µlTumor Lysis SyndromeVOD/SOSVomiting only studiesPublicationAuthorChalandon YDavies ADeAngelo DJFoà RGriffin TCGökbuget DGökbuget NGökbuget N, Hartog CHoelzer DJabbour EKantarjian HKopmar NLuskin MRMaude SLRausch CRausch CRZeidan AMDiseaseAkute lymphatische Leukämie, 18-55 JahreAkute lymphatische Leukämie, 56-75 JahreAkute lymphatische Leukämie, 56-75 Jahre, Ph/BCR-ABL+Akute lymphatische Leukämie, B/T lymphoblastisches LymphomAkute lymphatische Leukämie, lymphoblastische Lymphome, 18-55 JahreAkute lymphatische Leukämie, lymphoblastische Lymphome, 56-75 JahreAkute lymphatische Leukämie, lymphoblastische Lymphome, Therapieversagen oder MRD-Persistenz nach Konsolidation I,18-55 JahreAkute lymphatische Leukämie, Ph/BCR-ABL+, 18-55 JahreAkute lymphatische Leukämie, Rezidiv nach der ErstlinientherapieALL, rezidiviert oder therapierefraktärALL bei Frail Patienten, ErstlinieALL bei Frail Patienten, Ph/BCR-ABL+, ErstlinieB-/T-ALL, Ph/BCR-ABL-, 18-59 Jahre, ECOG < 4B-ALL, CD19+ rezidivierte oder refraktäre B-ALL, Lymphodepletion vor CAR T-Zell TherapieB-ALL, Ph/BCR-ABL+, 18-59 Jahre, ECOG < 4B-Vorläufer ALL, mit MRD > 0,1%, nach Chemotherapie B/T-ALL, Ph/BCR-ABL-, 18-59 Jahre, ECOG < 4Hochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, ErstlinieHochmaligne B-ALL bei Erwachsenen, RezidivtherapieHochmaligne B-ALL und B-NHL bei Erwachsenen, Erstlinieneudiagnostizierte akute lymphatische Leukämie, Ph+/BCR-ABL+, ECOG 0-1Primär therapierefraktäres oder rezidiviertes B-NHL oder B-ALL, <21 Jahre, ECOG 0-2refraktäre oder rezidivierende ALL, BCR-ABL/Ph negativ, Blasten > 5%, ECOG 0-2rezidivierende oder refraktäre ALL, CD-22+, ECOG 0-2T-ALL, 18-59 Jahre, ECOG < 3T-ALL, 18-59 Jahre, ECOG < 4T-ALL, erstes Rezidiv, 15-55 J.T-ALL, Ph/BCR-ABL-, 18-59 Jahre, ECOG < 4T-ALL/LBL, therapierefraktär oder rezidiviertT-ALL/T-LBL, therapierefraktär oder rezidiviertOriginAbramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine at the University of PennsylvaniaAnderson Cancer Center, Houston, TX, USACancer Research UK Centre, University of Southampton, UK, SABRINA StudieDepartment of Leukemia, University of Texas M.D. Anderson Cancer CenterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Cancer and Leukemia Group B study 19801Department of Medicine II, Goethe University Hospital, Frankfurt, GermanyDepartment of Translational and Precision Medicine, Sapienza University of RomeDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaGerman Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2003German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia, GMALL 07/2017GMALL Therapieempfehlung Frail ALL 2008Group for Research on Adult Acute Lymphoblastic Leukemia, GRAAL 2014/B und TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/B/T und GRAAPHGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/B und TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAALL 2014/ TGroup for Research on Adult Acute Lymphoblastic Leukemia, GRAAPH 2014Memorial Hospital of South Bend, South BendPerelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, ELIANA trialThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA, ENDEVOL regimenThe University of Texas MD Anderson Cancer Center, Houston, USAUniversity Hospital, Frankfurt, GermanyUniversity of Texas, MD Anderson Cancer Center, Houston, INO-VATEProtocols in Revision 121 protocols foundProtocols under revision.Blinatumomab (9/28), Acute Lymphoblastic Leukaemia, Cycle 1 (PID107)Blinatumomab (9/28), ALL/NHL, cycle 1 (PID2117)Blinatumomab 15, Acute Lymphoblastic Leukaemia, MRD positive (PID1140)Blinatumomab 28, Acute Lymphoblastic Leukaemia, maintenance (PID313)Blinatumomab 28, Acute Lymphoblastic Leukaemia, Cycle 2-5 (PID68)Blinatumomab 28, ALL/NHL, cycle 2-4 (PID2118)CLAEG - Cladribine 0.2 / Etoposide 60 / Cytarabine 1500, T- Acute Lymphoblastic Leukaemia (PID1907)Clofarabin 10 / Cyclophosphamide 600, B/T-Acute Lymphoblastic Leukemia (PID2269)Clofarabin 40, B/T-Acute Lymphoblastic Leukemia (PID2270)Cytarabine 40 / Dexamethasone 4 / Methotrexate 15, intrathecal, CNS Prophylaxis, Malignant Meningitis (PID602)Cytarabine 500 / Etoposide 150, Acute Lymphoblastic Leukaemia, Lymphodepletion (PID1832)Cytarabine 500 / Methotrexate 250 / Inotuzumab Ozogamicin 0.3 / Rituximab 375, ALL/NHL, cycle 2,4 (PID2097)Fludarabine 30 / Cyclophosphamide 500, Acute Lymphoblastic Leukaemia, Lymphodepletion (PID1831)GMALL - ALL - Frail patients, maintenance (week 14) (PID105)GMALL - ALL - Frail patients, maintenance option Cyclophosphamide (week 18,26,34,42,50) (PID85)GMALL - ALL - Frail patients, maintenance option Vincristine (week 18,26,34,42,50) (PID84)GMALL - ALL - Frail patients, induction (PID103)GMALL - ALL - Frail patients, reinduction, week 10 (PID104)GMALL - ALL - Frail patients, Pre-phase, all risk groups (PID102)GMALL - ALL - Frail, Induction + Maintenance, Ph/BCR-ABL+ (PID106)GMALL 08/2013 - ALL maintenance (week 40-51 and month 21-30), 56 - 75 years (PID720)GMALL 08/2013 - ALL maintenance (week 40-51 and month 21-30), 56 - 75 years, Ph/BCR-ABL+ (PID2139)GMALL 08/2013 - ALL maintenance (week 52 to month 20), 56 - 75 years (PID721)GMALL 08/2013 - ALL maintenance (week 52 to month 20), 56 - 75 years, Ph/BCR-ABL+ (PID662)GMALL 08/2013 - ALL maintenance, 18 - 55 years old (PID638)GMALL 08/2013 - ALL/LBL consolidation III and V (weeks 24, 32), 18 - 55 years (PID634)GMALL 08/2013 - ALL/LBL Consolidation IV (Week 30), 56 - 75 years (PID1097)GMALL 08/2013 - ALL/LBL Induction (Day 6), 18 - 55 years, Ph/BCR-ABL+ (PID964)GMALL 08/2013 - ALL/LBL Induction (Day 6), 56 - 75 years, Ph/BCR-ABL+ (PID1103)GMALL 08/2013 - ALL/LBL Induction I (Day 6), 18 - 55 years, all risk groups (PID592)GMALL 08/2013 - ALL/LBL Induction I (Day 6), 56 - 75 years (PID1087)GMALL 08/2013 - ALL/LBL Induction II (Day 20), 56 - 75 years (PID1088)GMALL 08/2013 - ALL/LBL Induction II (Day 23), 18 - 55 years, all risk groups (PID594)GMALL 08/2013 - ALL/LBL consolidation I (day 60), 18 - 55 years, all risk groups (PID595)GMALL 08/2013 - ALL/LBL consolidation I (day 60), 18 - 55 years, Ph/BCR-ABL+ (PID966)GMALL 08/2013 - ALL/LBL consolidation I (week 8), 56 - 75 years, Ph/BCR-ABL+ (PID639)GMALL 08/2013 - ALL/LBL Consolidation I (Week 9), 56 - 75 years (PID1086)GMALL 08/2013 - ALL/LBL Consolidation II (Week 14), 18 - 55 years (PID1098)GMALL 08/2013 - ALL/LBL consolidation II (week 14), 56 - 75 years, Ph/BCR-ABL+ (PID640)GMALL 08/2013 - ALL/LBL Consolidation II (Week 15), 56 - 75 years (PID1091)GMALL 08/2013 - ALL/LBL consolidation II in treatment failure/MRD persistence of T-ALL/T-LBL, 18 - 55 years (PID965)GMALL 08/2013 - ALL/LBL consolidation III and V (weeks 23, 33), 56 - 75 years, Ph/BCR-ABL+ (PID635)GMALL 08/2013 - ALL/LBL consolidation III and V (week 24,34), 56 - 75 yrs (PID1090)GMALL 08/2013 - ALL/LBL consolidation IV (week 29), 56 - 75 years, Ph/BCR-ABL+ (PID637)GMALL 08/2013 - ALL/LBL consolidation IV and VI (weeks 27, 35), 18 - 55 yrs (PID632)GMALL 08/2013 - ALL/LBL Reinduction (Week 18), 56 - 75 years, Ph/BCR-ABL+ (PID709)GMALL 08/2013 - ALL/LBL Reinduction (Week 19), 18 - 55 years (PID636)GMALL 08/2013 - ALL/LBL Reinduction (Week 19), 56 - 75 years (PID1096)GMALL 08/2013 - ALL/LBL Pre-phase, 18 - 55 yrs (PID591)GMALL 08/2013 - ALL/LBL Pre-phase, 56 - 75 yrs (PID1085)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part A (PID344)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part B (PID346)GMALL 08/2013 - B-ALL/NHL 2002 Regimen, 18 - 55, Part C (PID347)GMALL 08/2013 - B-ALL/NHL 2002 regimen, all ages, Pre-phase (PID345)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55, Part C, B-ALL only (PID357)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55,Part A, B-ALL only (PID355)GMALL 08/2013 - B-ALL/NHL 2002 regimen, older than 55,Part B, B-ALL only (PID356)GMALL 08/2013 - B-ALL/NHL 2002 regimen, Rituximab consolidation (PID784)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 5 (PID2087)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Ddoxorubicin 50 / Dexamethasone 40) / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 7 (PID2089)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 400, ALL/NHL, Ph/BCR-ABL+, intensification, month 7,19 (PID2113)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 3 (PID2086)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375 / Imatinib 800, ALL/NHL, Ph/BCR-ABL+, cycle 1 (PID2084)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40) / Rituximab 375, ALL/NHL, cycle 1,3 (PID2061)Hyper-CVAD (Cyclophosphamide 300 / Vincristine 2 / Doxorubicin 50 / Dexamethasone 40), ALL/NHL, cycle 5,7 (PID2063)Inotuzumab Ozogamicin 0.8, Acute Lymphoblastic Leukaemia, Cycle 1 (PID161)Inotuzumab Ozogamicin 0.8, Acute Lymphoblastic Leukaemia, Cycle 2-6 (PID145)Methotrexate 100 / Peg-asparaginase 2000 / Imatinib 400, ALL/NHL, Ph/BCR-ABL+, intensification, month 6,18 (PID2110)Methotrexate 100 / Peg-asparaginase 2000, ALL/NHL, intensification, month 6,18 (PID2074)Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 6 (PID2088)Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 8 (PID2090)Methotrexate 1000 / Cytarabine 3000, ALL/NHL, cycle 6,8 (PID2065)Methotrexate 12 / Cytarabine 100, Malignant Meningitis, CNS Prophylaxis (PID2575)Methotrexate 15 / Cytarabine 30, Burkitt's Lymphoma (PID2240)Methotrexate 15, Malignant Meningitis, CNS Prophylaxis (PID876)Mini-hyperCVD (Cyclophosphamide 150 / Vincristine 2 / Dexamethasone 20) / Inotuzumab Ozogamicin (0.6/0.3) / Rituximab 375, ALL/NHL, cycle 1 (PID2098)Mini-hyperCVD (Cyclophosphamide 150 / Vincristine 2 / Dexamethasone 20) / Inotuzumab Ozogamicin 0.3 / Rituximab 375, ALL/NHL, cycle 3 (PID2099)Nelarabine 1500, T-ALL/T-LBL (PID1922)Nelarabine 650 / Etoposide 100 / Cyclophosphamide 440, T-ALL/T-LBL (PID1926)Nelarabine 650 / Peg-asparaginase 1500, T-ALL, maintenance, month 6, 7 (PID2083)POMP (Mercaptopurine 50 / Methotrexate 10), ALL/NHL, maintenance, month 13-36, variant 1 (PID2120)POMP (Mercaptopurine 50 / Vincristine 2 / Methotrexate 10 / Prednisolone 50), ALL/NHL, maintenance, month 1-12, variant 1 (PID2119)POMP (Mercaptopurine 50 / Vincristine 2 / Methotrexate 20 / Prednisolone 200), ALL/NHL, maintenance, month 1-5,8-17,20-30 (PID2072)Prednisolone 60 / Dasatinib 140 - Blinatumomab 28 / Dasatinib 140, Acute Lymphoblastic Leukaemia, Part A (PID1678)Prednisolone 60 / Dasatinib 140 - Blinatumomab 28 / Dasatinib 140, Acute Lymphoblastic Leukaemia, Part B (PID1679)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 3, Burkitt's Lymphoma, Cycle 1-2. (PID2223)R-ICE - Rituximab 375 / Etoposide 100 / Carboplatin 5 / Ifosfamide 3, Burkitt's Lymphoma, Cycle 3. (PID2224)Rituximab 1400, single dose subcutaneous (PID310)Rituximab 375 / Methotrexate 1000 / Cytarabine 3000 / Imatinib 600, ALL/NHL, Ph/BCR-ABL+, cycle 2,4 (PID2085)Rituximab 375 / Methotrexate 1000 / Cytarabine 3000, ALL/NHL, cycle 2,4 (PID2064)GRAALL study - B- ALL maintenance, month 2,4,6-12, 18 - 59 years (PID985)GRAALL study - B-/T- ALL consolidation block S1, S4, S7 (day 1-14), 18 - 59 years (PID980)GRAALL study - B-/T-ALL maintenance, month 1,3,5, 18 - 59 years (PID983)GRAALL study - B-/T-ALL maintenance, month 13-24, 18 - 59 years (PID984)GRAALL Study - B-/T-ALL Induction, 18 - 44 Years (PID978)GRAALL study - B-/T-ALL induction, 45- 59 years (PID1027)GRAALL study - B-/T-ALL consolidation block S2, S5, S8 (day 15-28), 18 - 44 years (PID981)GRAALL study - B-/T-ALL consolidation block S2, S5, S8 (day 15-28), 45 - 59 years (PID1028)GRAALL study - B-/T-ALL consolidation block S3, S6, S9 (day 29-35), 18 - 59 years (PID982)Study GRAALL - B-/T-ALL salvage, 18-59 (PID979)GRAALL Study - B-/T-ALL Late Intensification, 18 - 44 years for patients without salvage therapy (PID986)GRAALL Study - B-/T-ALL Late Intensification, 18 - 59 for Patients with salvage (PID988)GRAALL Study - B-/T-ALL Late Intensification, 45 - 59 years for patients without salvage therapy (PID1032)GRAALL study - B-/T-ALL stand-by block, 18-59 (PID987)Study GRAALL - B-/T-ALL and GRAAPH - B-ALL Pre-phase (PID992)Study GRAALL - B-/T-ALL Waiting Block 1 and 3, 18-59 (PID1071)GRAALL Study - B-/T-ALL Waiting Block 2 and 4, 18-59 (PID1074)Study GRAALL - B-/T-ALL, CNS Treatment (PID1029)GRAALL study - T- ALL consolidation block T5, T8 (day 22-35), 18 - 59 years (PID990)GRAALL study - T-ALL maintenance, month 2,4,6, 18 - 59 years (PID994)GRAALL study - T-ALL maintenance, month 7-12, 18 - 59 years (PID993)GRAALL study - T-ALL consolidation block T4, T7 (day 1-21), 18 - 59 years (PID989)GRAALL study - T-ALL consolidation block T6, T9 (day 36-49), 18 - 59 years (PID991)GRAAPH study - B-ALL, interphase, Ph/BCR-ABL+ (PID1072)GRAAPH Study - B-ALL, Cycle 1, Ph/BCR-ABL+ (PID996)GRAAPH study - B-ALL, cycle 2 and 4, arm A, Ph/BCR-ABL+, 18-44 years (PID998)GRAAPH study - B-ALL, cycle 2 and 4, arm A, Ph/BCR-ABL+, 45-59 years (PID1073)GRAAPH Study - B-ALL, Cycle 2 and 4, Arm B, Ph/BCR-ABL+ (PID999)GRAAPH Study - B-ALL, Cycle 3, Ph/BCR-ABL+ (PID997)Vincristine 2 / Prednisolone 200 / Imatinib 400, ALL/NHL, maintenance, Ph/BCR-ABL+ (PID2073)Vindesin 3 / Methotrexate 1500 / Etoposide 250 / Cytarabine 2000 / Dexamethasone 10, Acute Lymphoblastic Leukaemia (PID2268)